Carbetocin LA is under clinical development by Ferring International Center and currently in Phase III for Hemorrhage. According to GlobalData, Phase III drugs for Hemorrhage have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Carbetocin LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Carbetocin LA overview
Carbetocin (Pabal, Duratocin, Caritec, FE-992097) is a long-acting oxytocin analogue acts as a gynaecological agent. It is formulated as an injectable solution for intravenous route of administration. Carbetocin is indicated for the prevention of uterine atony and postpartum haemorrhage following caesarean section under epidural or spinal anaesthesia.
It is under development for the treatment of hyperphagia in Prader-Willi syndrome and post partum hemorrhage. The drug candidate is a synthetic analogue of oxytocin, administered through intranasal route.
Ferring International Center overview
Ferring International Center (Ferring), a subsidiary of Ferring Holding SA, is a research-driven, specialty biopharmaceutical company. Its primary activities include research and development in reproductive medicine, women’s health, gastroenterology and urology. Ferring’s product portfolio includes treatments for reproductive medicine and maternal health, gastroenterology and microbiome, urology and uro-oncology, endocrinology, and orthopedics. Ferring’s products are used by patients seeking treatments in the areas of reproductive health, gastroenterology, and urology, among others. The company has a global presence with manufacturing sites and R&D centers in countries such as China, Denmark, Brazil, Israel, Japan, India, the UK, and the US. Ferring Pharmaceuticals is headquartered in Saint-Prex, Switzerland.
For a complete picture of Carbetocin LA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
